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Abstract 
 
Millions of individuals worldwide suffer from acute and, more severely, chronic pain 
conditions (e.g., neuropathic pain, and migraine). The latter bear tremendous personal, 
familial, and social costs, since sufferers and their relatives undergo a complete turnaround of 
their lives with the search of relief from pain becoming their pivotal thought. Sadly, to date no 
effective pharmacological approaches are available which can alleviate chronic pain 
significantly or in the long run in all patients. The current central strategy for the development 
of new and effective painkillers lies in the hypothesis that cellular and/or molecular players in 
nociception must exists that are not targeted by “classical” analgesics, and therefore 
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researchers have put tremendous efforts into the in-depth analysis of the pathways leading to 
pain development and maintenance over time. In this complex scenario, two outsiders are 
now taking the center stage: glial cells in sensory ganglia and in the central nervous system, 
thanks to their ability to communicate with neurons and to modulate their firing, and the 
purinergic system. Extracellular purine and pyrimidine nucleotides are involved in the 
physiology of virtually every body district, and their extracellular concentrations massively 
increase under pathological situations, suggesting that they might represent potential targets 
for the modulation of disease-associated symptoms, like pain. Here, we provide an overview 
of the present knowledge of the role of nucleotides in nociception, with a particular emphasis 
on G protein-coupled P2Y receptors and their involvement in the communication between 
first- and second-order neurons in sensory nerve pathways and surrounding glial cells.  
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1. Introduction 
 
 
 According to the International Association for the Study of Pain (IASP; 
http://www.iasp-pain.org/), pain is defined as “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage”. Chronic pain (like headache, migraine, cancer or neuropathic pain) persists over 
time as a consequence of a number of pathologies and diseases, and sometimes represents the 
pathology itself.  Regardless the cause, chronic pain has the power to dramatically affect the 
patients’ quality of life with enormous associated personal, social, and economic costs. It is 
estimated that, in the U.S. alone, more than 100 million people suffer from chronic pain, with 
an estimated cost from $560 billion to $635 billion, which combines the medical costs of pain 
care and the economic costs related to disability days and lost wages and productivity [1]. 
Moreover, despite the large number of marketed analgesic and painkiller drugs, many 
sufferers are (or slowly become) insensitive to the currently available pharmacological 
approaches [2], and to date no adequate therapies are available for some common types of 
chronic pain, such as neuropathic pain or migraine. 
Based on this scenario, research has focused on the in-depth understanding of causal 
mechanisms of pain generation and maintenance, in order to identify new promising cellular 
or molecular players, which can be exploited as pharmacological targets for innovative 
therapies. In this commentary, we focus our attention on one of these possible yet-to-be fully 
understood targets: the purinergic system, and in particular P2 nucleotide receptors. The role 
of nucleotides as neurotransmitters in the associative areas of the central nervous system 
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(CNS), where painful signals from the periphery are integrated and modulated, is currently 
virtually unknown. Conversely, at the periphery and in the spinal cord, nucleotides have 
emerged as relatively new players in pain development with the discovery that they can 
activate specific membrane receptors and that their extracellular concentrations rise to the 
micromolar range at any site of injury, tissue damage, or inflammation. We will briefly 
review already available data on the role of neuronal ionic P2X receptors, and we will then 
concentrate on G protein-coupled P2Y purinergic receptors in sensory nerve pathways.  
 
2. Classification of P2 receptors 
 
Adenosine-5'-triphosphate (ATP) has long been recognized as an intracellular energy 
supplier, but its acceptance as an extracellular signaling molecule has taken a considerably 
long period of time [3]. In 1972 Burnstock proposed a new role for ATP as a neurotransmitter 
in non-adrenergic, non-cholinergic nerves in the gut and bladder [4]. In the following years 
ATP metabolites derived from its enzymatic hydrolysis (such as nucleotide adenosine-5'-
diphosphate, ADP, and nucleoside adenosine, Ado, as well as other extracellular nucleotides 
like the uridine-5'-triphosphate,UTP, uridine-5'-diphosphate,UDP, and sugar nucleotides), 
also were  proposed as transmitters not only in sensory, but also in motor nerves and in CNS 
neurons [5,6], thanks to the discovery and cloning of specific receptors (see below). This new 
role of ATP, as a part of the complex extracellular network involved in cell-to-cell 
communication, has been established not only for fast neurotransmission, but also for a wide 
range of long-lasting biological processes, including release of cytokines, neurotransmitters 
and hormones, cell proliferation, differentiation and apoptosis in tissues as diverse as the skin, 
skeletal muscle, bone, nervous and immune system [5,6]. The first classification of purinergic 
receptors dates back to 1978, when Burnstock proposed criteria to differentiate these 
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receptors based on their natural ligands: the P1 receptors activated by Ado and antagonized by 
methylxanthines, and the P2 receptors, responding to nucleotides. To date, P2 receptors are 
further subdivided into two families: the ionotropic P2X receptors and the metabotropic P2Y 
receptors. P2X receptors are ligand-activated cationic channels, specifically activated by ATP, 
while P2Y receptors are activated by purine or pyrimidine nucleotides, or by sugar-
nucleotides, and couple to intracellular second-messenger systems through heteromeric G 
proteins [3]. In vertebrates, seven genes encode for P2X receptor subunits, which are 40-50% 
identical in their amino acid sequence. As of today, seven homomeric channels (P2X1-7) 
have been identified, but functional expression studies have also highlighted the existence of 
heteromeric receptors (e.g., P2X1/5 and P2X2/3) with subtly different pharmacology with 
respect to the homomeric counterparts [7]. P2Y receptors belong to the superfamily of G 
protein-coupled receptors (GPCR). Eight P2Y members (P2Y1,2,4,6,11,12,13,14) have been cloned 
in mammals [3]. From a pharmacological point of view, P2Y receptors can be broadly 
subdivided in four groups based on their responsiveness to nucleotides: i) adenine nucleotide-
preferring receptors, mainly responding to ADP and ATP (i.e., human and rodent P2Y1,12,13, 
and human P2Y11); ii) uracil nucleotide-preferring receptors, including the human P2Y4 and 
P2Y6 responding to UTP UDP, respectively; iii) receptors of mixed selectivity (i.e., human 
and rodent P2Y2, and rodent P2Y4 and, possibly, P2Y11); and iv) the P2Y14 receptor, 
responding to both UDP and sugar nucleotides (mainly UDP-glucose and UDP-galactose) 
with no differences among species [3]. The P2Y1,2,4,6,11 subtypes are coupled to Gq/G11 with 
subsequent activation of the PLC/IP3/Ca2+ signaling pathway, whereas P2Y12,13,14 inhibit 
adenylyl cyclase and cAMP generation through Gi/Go [3]. The P2Y2 subtype can couple to Gi 
as well, leading to the modulation of cell migration, at least in recombinant systems. The 
P2Y11 subtype has the unique property of also coupling to Gs, leading to the generation of 
cAMP. Activation of G proteins by P2Y receptors leads to a large variety of biological effects, 
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due to the subsequent engagement of different effectors, including MAP kinases, Rho kinase, 
phospholipase A2, nitric oxide, transactivation of growth factor receptors, and many others 
[5]. A list of agonists, antagonists, and main tissue distribution for the various P2Y receptor 
subtypes is provided in Table 1. The chemical structures of the synthetic agonists and 
antagonists listed in Table 1 can be found in Figures 1 and 2, respectively. 
 
3. Extracellular nucleotides and pain transmission 
 
 The first hints on a possible algogenic role for extracellular nucleotides date back to 
the 1960s, when a painful response was generated by the injection of ATP in the human 
blister base preparation [8] and ATP-induced pain and bronchospasm were demonstrated to 
be sensitive to aspirin [9]. 
In the 1980s, accumulating evidence led investigators to hypothesize the involvement 
of ATP in migraine [10], and in pain pathways in the spinal cord [11]. At the beginning of 
1990s, the rapid achievements in cloning, characterization, and evaluation of tissue 
distribution of the various P2 receptor subtypes (mainly of ionotropic P2X receptors) led to a 
progressive exponential growth in the number of published papers clearly confirming that 
ATP acts as an important neurotransmitter at sensory nerve pathways. Focusing on ionotropic 
P2X receptors was the most logical initial approach, due to their neuronal expression, their 
fast responses, and their ability to influence the intracellular ion concentrations, typical 
characteristics shared with other nociceptors. More recently, the contribution of metabotropic 
P2Y receptors to pain transmission has started to be recognized as well (Table 2). We will 
now briefly summarize what is currently known about the pro-algogenic role of the most 
studied P2 receptor, the P2X3 subtype, while emerging data on P2Y receptors will be 
discussed in the subsequent paragraphs. 
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3.1 Role of neuronal P2X receptors in nociception 
 
 The P2X3 subtype has become a central player in nociception, and consequently a 
potential pharmacological target for new anti-algogenic drugs, since its cloning and initial 
characterization. It was originally cloned from dorsal root ganglia (DRG) neurons [12], and it 
was later found to be highly expressed not only in small/medium diameter sensory neurons in 
DRGs and in trigeminal ganglia (TG), but also in neurons forming the subepithelial sensory 
nerve plexus in the walls of tubes (e.g., ureter, vagina, salivary and bile ducts, gut) and sacs 
(e.g., urinary and gall bladders, lung), as well as in the tongue and tooth pulp [13]. The 
regulation of gut functions by extracellular ATP is intriguing, since P2X3 receptors are 
localized not only on high-threshold sensory fibers mediating pain sensation, but also on low-
threshold sensory fibers controlling peristalsis [14]. Thus, moderate wall distension generates 
a sufficient extracellular ATP concentration to only activate peristalsis. Conversely, 
prolonged or more intense distension (e.g., due to stone transit in the ureter or bile duct) 
evokes massive ATP release from epithelial cells, which in turn activates P2X3 receptors on 
underlying sensory fibers with the generation of tremendous colic pain, [14]. Accordingly, 
P2X3 receptor antagonists could significantly reduce visceral pain.  
 A complex pattern of modulation of P2X3 receptor functions by known algogenic 
substances, such as NGF, BDNF and CGRP (which are released within the ganglion and 
contribute to the generation and modulation of painful sensations) through 
phosphorylation/dephosphorylation of specific serine and threonine residues in the P2X3 
receptor sequence has been demonstrated in TG sensory neurons. As a final outcome, 
recovery from P2X3 receptor desensitization is accelerated, and P2X3 activity is consequently 
increased [15,16,17]. Moreover, an increased expression of P2X3 receptors in TG neurons 
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was observed upon algogen application in vitro [15,18], or following induction of trigeminal-
associated pain in vivo (Fig. 1) [19,20]. Collectively, these data suggest that an extracellular 
milieu of pro-algogenic compounds profoundly modifies the amplitude and duration of P2X3 
receptor-mediated neuronal responses, which in turn contributes to the initiation and/or 
maintenance of TG pain, such as during a migraine attack. A role for P2X3 receptors in 
migraine is further supported by the recent observations that P2X3 receptor segregation to 
lipid rafts is significantly increased in TG neurons in a genetic mouse model of migraine, the 
CACNA1A knock-in (KI) mice [21]. As a consequence, the increased amplitude of P2X3-
mediated calcium responses and slower desensitization of the receptor are observed in KI 
mice than in wild-type (WT) mice [22]. The CACNA1A KI mice bear a gain-of-function 
mutation of the α subunit of the Cav2.1 neuronal calcium channel, which is typically detected 
in families suffering from familial hemiplegic migraine type 1 (FHM1), a severe and genetic 
form of migraine accompanied by hemiparesis [23]. KI mice show a higher sensitivity to the 
generation of Cortical Spreading Depression (CSD, the prodromic sign of migraine pain) and 
also a higher rate of release of pro-algogenic substances (such as CGRP) within the TG 
[24,25]. Taken together, the biochemical changes observed in purinergic transmission both at 
the central and the peripheral levels in KI mice could account for the higher susceptibility to 
migraine triggers in these animals (and, possibly, FHM1 patients) (see also below, Section 
5.2). 
It is also worth mentioning that the interest in P2X3 receptors in nociception is further 
increased by their possible involvement in the mechanism of action of known analgesic 
treatments. For example, it has been recently shown that the NSAID drug, naproxen, inhibits 
P2X3 activation in trigeminal ganglia [26]. Indeed, bioactive molecules (i.e., 
tetramethylpyrazine, sodium ferulate, and puerarine) contained in analgesic remedies utilized 
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in the traditional Chinese medicine also are known to inhibit P2X3-mediated transmission in 
primary afferent neurons [27]. 
The distinctive localization at sites where pain sensations are generated and processed 
has rendered the P2X3 receptor subtype as the most studied purinoceptor in nociception, 
although up to now the massive preclinical efforts in vitro and in vivo to understand its 
function and modulation have not led to a satisfactory clinical outcome, mostly due to the 
lack of selective antagonists with such a chemical structure that could be exploited in human 
studies. With the recent discovery of innovative chemical scaffolds for P2X3 antagonists, the 
first Phase 2 “proof-of-concept” studies are currently underway for inflammatory, visceral, 
and neuropathic pain patients [28]. 
P2X subtypes other than the P2X3 (e.g., the P2X4 subtype) are expressed by TG 
neurons [29], but their role in pain transmission has not yet been established. 
 
4. Modulation of pain transmission by P2Y receptors in sensory neurons 
 
In comparison to the key role played by neuronal P2X receptor subtypes (see Section 
3), the specific contribution of P2Y receptors to physiological and pathological pain has been 
less understood. This has been mainly due to their complex pharmacology and to the long-
standing lack of selective ligands for different P2Y receptor subtypes, an issue that has only 
recently started to be resolved (Table 1; Figures 1 and 2).  Messenger RNAs for 
P2Y1,2,4,6,12,13,14 subtypes have been found in DRG neurons [30,31,32], suggesting that these 
receptors may play an ancillary role in peripheral somatosensory transmission [33,34]. P2Y 
receptors are located not only in the cell body, but also in peripheral and central terminals 
[35,36], where their activity is presumably integrated within the complex molecular network 
associated with the transmission of nociceptive signals to the CNS. 
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Functional P2Y1,2,4 receptors are also expressed in subsets of TG sensory neurons [30, 
37], but to date their role in the modulation of trigeminal pain has not been properly 
investigated. 
At the moment, there is limited evidence to suggest that P2Y4 and P2Y6 receptors play 
a role in nociception, and therefore most of the scientific interest has been focused 
predominantly on P2Y1 and P2Y2 receptors subtypes. 
From a functional point of view, the preferential P2Y1-agonist ADP (but also P2Y12,13; 
see below) was found to inhibit the N-type voltage-gated calcium channels (VGCC) in rat 
DRG neurons. The outcome of VGCC inhibition is a decrease in sensory transmitter release 
from DR terminals in the spinal cord, which in turn diminishes transmission in ascending 
spinal nerve (pain) pathways [38]. P2Y receptor expression in sensory nerve terminals could 
control ATP actions on algogenic P2X subtypes, as well. In fact, P2Y1 and P2X3 receptors 
are often coexpressed in the same DRG neurons [30], and functional studies have shown that 
P2Y1 receptor activation leads to P2X3 receptor inhibition [39].  
Collectively, these data seem to point to anti-algogenic effects of ADP under some 
conditions; nonetheless, recent data suggest  an opposite effect for P2Y1 receptor subtype in 
pain induction. Instead, inhibition of VGCCs was later suggested to be mediated by the ADP-
activated P2Y12 subtype rather than by P2Y1 receptors [32]. Moreover, P2Y1 receptors were 
reported to mediate hyperalgesia [32], possibly through the sensitization of TRPV1 channels 
[40]. These collective findings suggest that, at least in DRG neurons, different classes of 
ADP-activated P2Y receptors act oppositely in modulating painful sensations, with the Gq-
coupled P2Y1 subtype exerting pro-algogenic effects and the Gi-coupled P2Y12,13 subtypes 
playing an analgesic role, although the real scenario is still far from being fully understood 
(see below). 
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Also activation of P2Y2 receptors can excite DRG neurons [41], but again the 
underlying mechanism remains obscure. This receptor subtype can sensitize TRPV1 channels 
in mouse DRGs [33,42], and modulate pro-algogenic neuropeptide release. In fact, the P2Y2,4 
preferential agonist, UTP, can induce the release of CGRP from rat DRG neurons [43]. Other 
studies have failed to confirm a direct release of CGRP by UTP, but instead have suggested 
that UTP can enhance acid buffer solution- and capsaicin-evoked neuropeptide release [44,45]. 
Additionally, UTP has been reported to activate capsaicin-sensitive cutaneous C-fibers [46], 
supporting a role for UTP as endogenous nociceptive messenger. Moreover, after CFA-
induced inflammation, P2Y2-/- mice failed to develop thermal hyperalgesia, with no difference 
in the extent of mechanical allodynia with respect to WT mice [42]. These results demonstrate 
that neuronal P2Y2 receptor subtype is predominantly involved in thermal nociceptive 
transmission.  
Nucleotides were also suggested to enhance nociception by modulating voltage-gated 
Na+ channels in DRG neurons [47], although the involvement of specific P2Y receptor 
subtypes is unclear. In addition, P2Y receptors control the function of several neuronal K+ 
channels, including KV7 [48], Kir3.1/3.2 [49], and KCa2 channels [50].  
It has been shown that ATP, ADP, and UTP (but not UDP) caused cell depolarization 
when applied to DRG neurons under current- and voltage-clamp, and enhanced the action 
potential discharge rate during current injections. The P2Y2 receptor-preferring agonist 2-
thio-UTP was equipotent to UTP in eliciting these effects, whereas the selective P2Y1 
receptor antagonist MRS2179 largely attenuated the excitatory effects of ADP, but left those 
of 2-thio-UTP unaltered. Application of either ADP or 2-thio-UTP inhibited K-currents 
through KV7 channels, and, in parallel, facilitated cation-current through TRPV1 channels, 
suggesting that the excitatory effects of these nucleotides were mediated by either P2Y1 or 
P2Y2 receptor subtypes which acted downstream through a common signaling pathway [51]. 
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Together with their already-mentioned ability to modulate VGCCs (see above), these 
observations reveal an increasingly important role for P2Y receptors in DRG neurons in 
controlling ionic currents, which has profound implications for neuronal firing and sensitivity 
to noxious stimuli. 
As previously mentioned for the P2X3 receptor subtype (see Section 3), P2Y receptor-
mediated signaling is characterized by significant plasticity upon chronic painful conditions, 
and this feature could be exploited in analgesic therapy (Figure 3; see below, Section 6). 
P2Y1 mRNA is upregulated in rat DRG cells after peripheral axotomy of the sciatic 
nerve [52], and again after CFA injection in the mouse hindpaw, whereas P2Y2,4,6 mRNAs are 
downregulated [42]. Conversely, both P2Y1 and P2Y2 mRNAs are upregulated in mouse 
L2/L3 DRG cells at 14 and 21 days after nerve transection [53]. The upregulation of P2Y1 
mRNA in mouse DRGs appears to be necessary for heat sensitization of cutaneous polymodal 
nociceptors in response to CFA injection in the skin [54]. Although the evaluation of the 
mRNA expression levels has been performed on total ganglia, and a contribution of glial P2Y 
receptors to detected increases cannot be excluded (see also below), these results indicate that 
neuronal P2Y receptors are likely to contribute to the plasticity of pain signalling upon 
chronic or inflammatory conditions, and could represent interesting targets for the 
development of new analgesics. 
Finally, it is known that dorsal horn spinal cord neurons at least express P2Y1,2,4 
receptor subtypes [31,55,56], although a full characterization and cellular localization of the 
various receptor subtypes has not yet been performed. Interesting results have been obtained 
following the intrathecal administration of uracil nucleotides in vivo. Here, UTP and UDP 
produced significant anti-allodynic effects following partial ligation of the sciatic nerve, and 
elevated the mechanical nociceptive threshold as well as prolonging the thermal nociceptive 
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latency in uninjured rats, thus suggesting an antinociceptive role for the P2Y2, P2Y4 and, 
possibly, P2Y6 receptor subtypes – for which UTP and/or UDP are agonists [57]. 
 
5. New emerging players in nociception: glial cells and purinergic transmission  
 
 Far from acting passively as a scaffold or as metabolic suppliers for the neuronal 
network, glial cells have now taken center stage in neurotransmission, thanks to their ability 
to react to either injury or metabolic dysfunction and to influence neuronal firing. As detailed 
below, their contribution to nociception is now firmly acknowledged, both in the periphery 
and in the CNS (with a primary role played here by microglia and astrocytes) [58] . Within 
sensory ganglia, the somata of sensory neurons are surrounded and wrapped by a network of 
satellite glial cells (SGCs), which continually monitor the extracellular milieu and exchange 
information with one another and with neurons as well, so profoundly affecting neuronal 
firing and, ultimately, the transmission of painful sensations [59,60]. Thus, targeting glial 
cells with specific pharmacological compounds has recently emerged as an exciting 
opportunity for the development of new and effective painkillers. 
Unveiling the whole molecular network involved in neuron-to-glia communication is 
mandatory to the identification of promising glial targets for analgesia, although the large 
number of currently recognized transmitters (including cytokines, growth factors, 
neurotransmitters and others) has sometimes frustrated researchers’ efforts in this endeavor. 
The purinergic system has emerged as one of the key players in cell-to-cell communication in 
many tissues and organs, and this is particularly true in the case of pain pathways. As already 
mentioned, purinoceptors are widely expressed in all the cell types involved in nociception 
(Table 2), and large amounts of purines and pyrimidines are released during physiological 
neurotransmission, and, more so, following tissue damage. Nucleotide release can be further 
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increased under inflammatory conditions or in the presence of pro-algogenic factors, such as 
growth factors and cytokines [61]. Moreover, a somatic release of ATP has been 
demonstrated within sensory ganglia, which can further enhance the exchange of information 
between neurons and glial cells, ultimately leading to the modulation of painful sensations 
[62].  
 
5.1 Spinal cord microglia and astrocytes 
 
 Spinal cord microglia quickly react to injury (including peripheral nerve damage), by 
first acquiring a phagocytic phenotype and then releasing large amounts of inflammatory 
mediators [63]. This pro-inflammatory extracellular milieu can dramatically influence 
synaptic activity and neuronal firing of second-order neurons in the spinal cord dorsal horn, 
and ultimately contribute to the generation and maintenance of chronic neuropathic pain [63]. 
Several damage-released mediators are involved in microglia activation, with extracellular 
ATP being one of the most important. The first and best studied purinergic receptor in 
microglia activation is the ionotropic P2X4 subtype, whose upregulation and activation in 
ipsilateral activated microglia following the chronic constriction injury (CCI) of the sciatic 
nerve turns out to be necessary for the development of tactile allodynia (Figure 4) [64]. 
Activation of the P2X4 receptor leads eventually to the activation of p38 and release of 
BDNF [65,66]. Up-regulation of the P2X4 receptor in spinal cord microglia was later 
demonstrated to require the CCL21 chemokine, which is expressed only in damaged neurons 
[67], and turned out to be necessary for the development of nerve injury-induced tactile 
allodynia and, to a lesser extent, peripheral inflammation [68]. It is worth mentioning that the 
prolonged activation of the P2X4 receptor opens a non-cytolytic pore that allows the efflux of 
large inflammatory and immune mediators from activated microglia, so contributing to 
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neuropathic pain [69]. Modulation by a phospholipase C-coupled pathway of the P2X4 pore-
opening phenomenon in microglia tantalizingly suggests a possible cross-talk between G 
protein-coupled (possibly purinergic) receptors and the P2X4 subtype. 
 In fact, P2Y receptors may be directly involved in spinal cord microglia activation 
under painful conditions. Messenger RNAs for the P2Y2,6,12,13,14 subtypes have been detected 
in primary microglia [70]. The UDP-sensitive P2Y6 receptor subtype appears to be directly 
involved in the modulation of microglia phagocytosis [71], whereas a prominent role has been 
proposed for the P2Y12 subtype in the development of allodynia following nerve injury. In the 
latter case, an ipsilateral and time-dependent up-regulation of microglial P2Y12 was observed 
following nerve ligation, whereas the genetic ablation of P2Y12 receptor expression or 
administration of P2Y12 selective antagonists (i.e., intrathecal AR-C69931MX or oral 
Clopidogrel) prevented the development of tactile allodynia [72]. Moreover, intrathecal 
infusion of the P2Y12 agonist 2-(methylthio)-ADP in naïve rats mimicked nerve injury-
associated p38 activation and pain behavior [73]. It was also demonstrated that P2Y12 
receptors regulate microglial process extension and chemotaxis towards ATP by acting 
through integrin β1 [74], thus further confirming  a pivotal role for the P2Y12 receptor subtype 
in controlling microglial functions, and the development of neuropathic pain. 
  However, the complexity of the purinergic modulation has just started to emerge for 
microglial cells involved in pain development. In fact, not only mRNA for P2Y12, but also for 
P2Y6,13,14 are up-regulated in microglia in the ipsilateral spinal cord following nerve injury, 
and a mixture of P2Y6, P2Y12 and P2Y13 selective antagonists showed a longer suppressive 
effect on pain behavior than did  single treatments alone [75]. 
 Astrocytes, as well as microglia, are directly involved in pain transmission in the 
spinal cord, thanks to their ability to modify and modulate neuronal firing and to secrete pro- 
and anti-inflammatory and algogenic molecules; accordingly, they are now recognized as 
	   19 
therapeutic targets for chronic pathological pain, by virtue of their delayed activation with 
respect to rapidly-reacting microglia [58]. Cortical brain astrocytes express the full 
complement of P2Y and P2X receptors, with significant changes in the expression level 
following traumatic or ischemic events [76]. The purinergic system is directly involved in 
modulating reactive astrogliosis and astrocyte secretion of cytokines and chemokines in the 
brain cortex [76]. Thus, although the role of purinergic receptors in the modulation of spinal 
cord astrocytic functions following traumatic events and in nociception has not been directly 
addressed. However, the available evidence suggests that targeting astrocytic P2 receptors 
might represent a new option for the treatment of chronic painful conditions (see also below).  
 
5.2 Satellite glial cells in sensory ganglia 
 
 As already mentioned, SGCs wrap around the cell bodies of primary neurons in sensory 
ganglia, forming a morphological and functional unit [59]. The key role of SGCs in the 
development and maintenance of chronic pain has been demonstrated by their increased 
expression and release of IL-1β [77], TNFα [62], as well as by the increased gap junction-
mediated cell coupling [78,79] following nerve injury. Like other glial cells, SGCs also 
respond to nerve injury by up-regulating the expression of glial fibrillary acidic protein 
(GFAP) and undergoing division in response to chronic pain [77, 80]. Altogether, these 
changes lead to increased excitability of both primary afferents and CNS neurons, and the 
development of hyperalgesia and allodynia [81]. Indeed, inhibiting the expression of one of 
the major gap junctions subunits expressed by glial cells (i.e., Connexin 43) [82] by RNA 
interference in the TG resulted in a strong reduction of pain behavior in a model of facial 
neuropathic pain [83].  
 Trigeminal satellite glial cells express functional P2Y1,2,4,6,13 receptor subtypes under 
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basal conditions [37,84], whereas glial P2Y expression in DRG cells has been only evaluated 
at the mRNA level in rodents [31]. Those P2 purinergic receptors expressed by SGCs 
participate primarily in bidirectional neuron-glial communication [60], thanks to the somatic 
release of ATP within the sensory ganglion [62]. Released ATP may activate P2X7 receptors 
in SGCs, leading to the release of TNFα, which in turn can potentiate P2X3-mediated ATP 
currents in neurons (see also below) [62]. 
In recent years a close interplay between the purinergic system and other classical pain 
transducing signals within the TG has been elucidated, starting from the observation that 
chronic exposure of TG cultures to the algogenic mediator bradykinin (BK) induced the 
upregulation of P2Y-mediated calcium signaling in SGCs [37]. BK did not act directly on 
glial cells, but rather activated neuronal BK receptors, and, subsequently, caused the release 
of CGRP, which, in turn, stimulated the ERK1/2 MAP kinase signaling pathway in 
surrounding SGCs and increased P2Y receptor-mediated intracellular calcium responses. 
SGCs ultimately release a wide range of pro- and anti-algogenic cytokines and chemokines, 
which likely further contribute to communication with neurons and modulation of pain 
transmission (Figure 3) [24]. Pharmacological studies have revealed that those specific glial 
purinoceptors potentiated by CGRP are the P2Y1 and P2Y2 subtypes (Figure 3) [Ceruti et al., 
manuscript in preparation], although their exact role in pain modulation has not yet been 
evaluated in vivo. Interestingly, the anti-migraine drug, sumatriptan, inhibited BK-mediated 
CGRP release from TG neurons and P2Y receptor potentiation on SGCs, suggesting that 
modulation of the neuron-to-SGC communication network, which involves CGRP and P2Y 
receptors, is itself  involved in the anti-migraine effect of triptans [24]. Additionally, this 
network of interaction between neurons and SGCs is overactivated in CACNA1A KI mice 
(see Section 3) [23,24], providing additional clues on a possible role for extracellular 
nucleotides in the initiation and maintenance of migraine pain. These data clearly indicate that 
	   21 
the complex interplay between TG neurons and SCGs could become even more important 
under pathological conditions, when massive amounts of algogens are released within the TG, 
and highly active glial P2Y receptors may significantly contribute to pain transduction, thus 
representing a novel target for the pharmacological modulation of migraine pain.  
The complexity and plasticity of the purinergic control of neuron-to-SGC 
communication within the TG were further demonstrated by bidirectional calcium signaling 
between neurons and SGCs (which is diminished by the non-selective P2 antagonist suramin), 
and a switch from P2Y to P2X receptor subtypes under pathological conditions. In fact,  the 
amplitude of Ca-signaling among SGCs and between SGC-to-neuron was increased following 
induction of submandibular inflammation by CFA injection, whereas the amplitude of Ca-
signaling from neuron-to-SGC was reduced [60]. Moreover, the intracellular calcium 
response to ATP was mediated by P2Y receptors in control tissues, whereas the response was 
predominantly due to ionotropic P2X receptors after CFA-induced inflammation, suggesting 
that inflammatory conditions not only induce a large increase in the sensitivity of SGCs to 
ATP, but also a switch in ATP signaling through P2Y receptors to P2X receptors [85].  
The role of the P2Y12 receptor subtype within sensory ganglia is noteworthy for its 
possible clinical implications (see Section 6). Despite the detection of P2Y12 mRNA in total 
mouse TG and of functional protein on a limited percentage of SGCs in culture [37], 
surprisingly no P2Y12 immunostaining was detected on TG sections- a finding which 
suggested that the receptor protein is not expressed within the ganglion, but in the boundary 
area with the trigeminal nerve [80]. Interestingly, a recent study demonstrates the involvement 
of glial P2Y12 receptor subtype in trigeminal neuropathic pain. P2Y12 expression appeared in 
TG in GFAP-positive cells, but not in neurons after induction of lingual neuropathic pain. 
More importantly, administration of the P2Y12 antagonist MRS2395 significantly decreased 
the number of TG neurons encircled with activated (GFAP-positive) SGCs, and reverted the 
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lowered threshold for the head-withdrawal reflex in response to mechanical and heat 
stimulation of the tongue [86]. Thus, data show that activation of TG SGCs following 
induction of neuropathic pain leads to the expression of P2Y12 receptor, which is causally 
involved in the enhancement of TG neuron activity and nocifensive reflex behavior, 
contributing to the development of neuropathic pain.  
Concerning the expression and function of P2Y receptors in SGCs from DRGs, in situ 
hybridization histochemistry (ISHH) has detected mRNA expression only for the P2Y12 and 
P2Y14 subtypes [31]. Later on, immunofluorescence studies showed a detectable, yet low, 
level of P2Y1 expression [87]. Although no data are available, it is tempting to speculate that, 
among the various ganglion cell populations, the same molecular interplay involving the 
purinergic system and other known pro-algogenic mediators takes play in DRGs as well as 
TG, and could therefore lead to the development and maintenance of neuropathic pain. 
As mentioned above [85], ionotropic P2X receptors may also contribute to neuron-to-
SGC exchange of information within sensory ganglia, with the P2X7 receptor subtype 
possibly playing a major role. P2X7 receptor is highly expressed in immune cells, microglial 
cells, and astrocytes, as well as SGCs in the DRG and TG [62,85,87]. P2X7 represents a 
special member of the P2X ionic receptor family, since under specific conditions (e.g., 
repeated ATP stimulation or high extracellular ATP concentrations) it can open a membrane 
pore, permeable to solutes up to 900 Da and which cannot be done by any other member of 
the P2X receptor subfamily [7], so allowing the flux of bioactive molecules between the 
extracellular and intra-cellular compartments.  
The role of P2X7 in the modulation of nociception is controversial. In support of an 
involvement, P2X7-KO mice showed a complete inhibition of chronic inflammatory and 
neuropathic pain, likely due to the lack of P2X7 receptor expression on inflammatory and 
immune cells [88]. In line with this pre-clinical observation, a genetic variance leading to 
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impaired pore formation has been linked to lesser susceptibility to chronic pain not only in 
rodents, but, more interestingly, in two cohorts of human patients with chronic pain (i.e., 
mastectomy- and osteoarthritis-related pain) [89]. Although no analysis of P2X7 receptor 
expression was provided at the cellular level, these observations push forward the P2X7 
receptor as a possible target for the development of new effective agents against chronic pain, 
but also alert clinicians to the need for patient genotyping when anti-P2X7 strategies are 
studied, since patients carrying the defective haplotype would not benefit from this 
therapeutic approach. 
However, conflicting results have been reported for P2X7 at the DRG level. An initial 
paper demonstrated that ATP released from neuronal somata activated P2X7 receptors on 
surrounding SGCs, which resulted in the release of TNFα and potentiation of neuronal P2X3 
receptor function [62]. Although no in vivo data were provided, a pro-algogenic role for DRG 
glial P2X7 receptors was hypothesized, in accordance with the above-mentioned papers. 
However, the same group later showed an unexpected ability of P2X7 receptors in SCGs to 
inhibit the function of neuronal P2X3 receptor in DRGs [87], through the involvement of 
neuronal P2Y1 receptors; the functional outcome of this effect is a reduction of inflammatory 
pain in rats. Whether these opposite effects exerted by glial P2X7 receptors are due to the 
specific pain paradigm utilized is not known, but once again conflicting data advocate caution 
when trying to draw general conclusions on the pro- or anti-algogenic role of a specific 
purinergic receptor subtype, an issue which further complicates research in this field. 
 
6. Progress towards therapeutic interventions 
 
Based on the experimental evidence presented, it has become increasingly apparent 
that the purinergic system significantly contributes to nociceptive signaling. Purinergic 
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receptors are therefore particularly attractive as targets for the development of innovative 
pharmacological entities against pain. However, the complexity of the system poses, several 
limitations, or potential pitfalls, in the translation to the clinic. The first difficulty is intrinsic 
to the study of nociception, not only by the existence of several different types of pain (e.g., 
visceral, neuropathic, acute, inflammatory etc.), but by the use of various in vivo models for 
the pre-clinical study  of these types of pain. It has proven to be extremely difficult to draw 
generalized conclusions based on in vitro or pre-clinical in vivo data, apart from one specific 
type of pain (visceral pain) where the P2X3 subtype plays a prominent role [28]. Moreover, 
the large number of P2 receptor subtypes involved (to which P1 receptors responding to 
adenosine should be added also) [3], and long-standing lack of selective ligands to clearly 
identify the roles of specific P2 receptor subtypes in preclinical studies has complicated the 
identification of specific purinergic targets. To overcome this long-standing absence of 
selective ligands, many important results have been obtained using genetically modified 
animals, but a key issue to be addressed is the real translational potential of data obtained in 
knock-out animals. In fact, by selectively lacking one (or more) protein or receptor, knock-out 
mice have undoubtedly significantly contributed to a better understanding of the molecular 
pathways controlling pain transmission. Nevertheless, when trying to identify new molecular 
druggable targets, the data can be puzzling. Concerning the purinergic system, total inhibition 
of pain and development of allodynia following nerve injury has been observed in P2X4-KO, 
and also in P2Y12-KO mice [68,72] (see above for details), indicating that the blockade of one 
or both of these receptors is sufficient to relieve neuropathic pain. So, based on these results 
what is the best purinergic target for drug development in pain in humans? Is it possible to 
think of a non-selective multi-target agent acting on different purinergic receptor subtypes 
simultaneously for neuropathic pain? 
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In the search of new pharmacological entities to relieve pain, it has become 
increasingly clear that focusing on one single molecular target probably does not represent the 
best option. Promising in vitro and preclinical observations on drugs acting selectively on a 
single target have disappointingly turned out to be impossible to reproduce in vivo. As a 
consequence, many potential analgesic drug candidates have been abandoned at early stage in 
preclinical trials because of their poor nociceptive activity (e.g., neurokinin 1 receptor 
antagonist) [90]. To further confirm this issue, the “old” drugs currently utilized in CNS 
therapeutics (and in some kinds of pain as well) do not act selectively on one single target, but 
rather on multiple molecular targets [90]. Thus, for example if a new molecule acting on the 
P2X4 and P2Y12 receptors could be designed and synthesized, its use in neuropathic pain 
might lead to better results than drugs designed to be more selective for one or other P2 
receptor subtype. As far as the P2Y12 subtype is concerned, selective antagonists are already 
available in the clinic (e.g., Clopidogrel, and more recently, Prasugrel and Ticagrelor), and 
have been used as anti-platelet agents for some time [91]. This anti-platelet effect, which can 
be foreseen for P2Y1 selective antagonists as well, although to a lesser extent, would of 
course represent potential side effects for an analgesic.  In addition, the complexity and 
widespread distribution of purinergic receptors throughout the body suggests the possible 
development of additional adverse effects when targeting specific receptor subtypes (for 
example on peristalsis and immune functions). The synthesis and development of effective 
multitarget drugs can help overcoming this issue, due to their lower affinity at single receptor 
subtypes with respect to compounds selectively targeting only one specific receptor. It is also 
tempting to speculate that targeting specific P2 receptor subtypes could also reduce the 
development of side effects thanks to the wider therapeutic range under painful conditions. In 
fact, P2 receptors are up-regulated and sensitized along the pain signaling pathways (see 
	   26 
above), and likely respond to lower ligand concentrations than receptors expressed in non-
affected body districts. 
Finally, all the various cell types involved in the pain pathways from the periphery to 
the CNS also express numerous purinergic receptors (Table 2), whose numbers are 
dynamically regulated by induction of pain (Figures 3 and 4). Focusing on G protein-coupled 
P2Y receptors could represent an interesting option in one sense, since these receptors are 
expressed at both the neuronal and glial level (in contrast to P2X receptors which are mostly 
neuronal), and, therefore, antagonists acting on common subtypes (for example, the P2Y1 and 
P2Y2 receptors in sensory ganglia; Figure 3) could modulate pain transmission at multiple 
levels, especially if the target receptor is upregulated by painful conditions. In this case, a 
different kind of multitarget approach can be hypothesized so that the same target (for 
example, one or more P2Y purinergic receptors) is inhibited (or activated depending upon its 
pro- or anti-algogenic activity) at different cellular and tissue sites at the same time (e.g., on 
glial cells, neurons, in the periphery or in the spinal cord).  
 
7. Conclusions 
 
 Available evidence indicates that targeting the purinergic system represents an 
innovative therapeutic option in the fight against acute and chronic pain states, due to its 
important role in the modulation of cell-to-cell communication at multiple sites along the pain 
signaling pathways from the periphery to the CNS. More work is needed, however, to fully 
understand the real pro- or anti-algogenic effects induced by the various receptor subtypes 
involved, in particular glial P2Y receptors. Moreover, a closer collaboration among experts in 
pharmacology, biochemistry, molecular biology, and pharmaceutical chemistry is mandatory 
to clearly identify the most promising druggable targets, which could be successfully utilized 
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in preclinical and clinical studies to accelerate the process towards new therapeutic options 
for the huge amount of pain patients worldwide.  
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FIGURE LEGENDS 
 
Figure 1. Chemical structures of selective agonists at the various P2Y receptor subtypes. 
IUPAC chemical names can be found in the list of Abbreviations. 
 
Figure 2. Chemical structures of selective antagonists at the various P2Y receptor 
subtypes. IUPAC chemical names can be found in the list of Abbreviations. 
 
Figure 3. Expression of various subtypes of ionotropic P2X and G protein-coupled P2Y 
nucleotide receptors in sensory ganglia (DRG and TG) and their plasticity upon painful 
conditions. Sensory neurons or surrounding satellite glial cells (SGCs) express a number of 
P2X and P2Y receptor subtypes under basal conditions. Upon induction of chronic pain, the 
expression levels of several P2 receptors are significantly elevated (as evaluated either at the 
mRNA or protein level), as shown in the right panel by the increased line weight. Indeed, the 
P2Y12 receptor subtype is expressed by SGCs only under painful conditions. As detailed in 
the text, conflicting results have been published for some receptor subtypes (e.g., neuronal 
P2Y2,4,6 receptors were found down-regulated in rat DRGs) [42]. Purinergic receptors are 
involved in the cross-communication between neurons and SGCs, in close collaboration with 
other known pro-algogenic mediators that are released in the intercellular space by either cell 
types (see box). Moreover, they can also either positively or negatively modulate the function 
of other nociceptors, such as TRPV1 or sodium, potassium, and calcium channels (see text for 
details).  
 
Figure 4. Expression of various subtypes of ionotropic P2X and G protein-coupled P2Y 
nucleotide receptors in the dorsal horn spinal cord and their plasticity upon painful 
	   39 
conditions. A number of P2X and P2Y receptor subtypes are expressed by spinal cord 
microglia, and modulate microglia activation and reaction to traumatic events. Only sporadic 
reports on the expression of some P2 receptor subtypes by spinal neurons or astrocytes are 
currently available (see text for details). P2X3 purinergic receptors are expressed at the 
central terminals of DRGs sensory neurons innervating the spinal cord tissue. Nerve injury or 
inflammatory conditions induce the up-regulation of microglia purinergic receptors (as 
evaluated either at the mRNA or at the protein level; right panel, increased line weight), 
which promote microgliosis, and the consequent release of pro-inflammatory and pro-
algogenic substances. The same process can be foreseen for astrocyte purinoceptors as well. 
 
 
Subtype Natural agonist(s) 
Synthetic 
agonist(s) 
Selective 
antagonist(s) Main tissue distribution 
P2Y1 ADP 
2-MeSADP 
ADP-β-S 
MRS2365 
MRS2500 
MRS2179 
Epithelial and endothelial 
cells, platelets, immune 
cells, osteoclasts, brain 
P2Y2 UTP/ATP 
MRS2698 
MRS2768 
UTP-γ-S 
INS37217 
PSB-716 
AR-C126313 
Immune cells, epithelial 
and endothelial cells, 
kidney tubules, 
osteoblasts 
P2Y4 UTP/ATP 
2’-azido-2’-
deoxyUTP Not yet available 
Endothelial and epithelial 
cells, placenta, spleen, 
thymus 
P2Y6 UDP 
PSB-0474 
UDP-β-S 
INS48823 
MRS2693 
MRS2578  
Airway and intestinal 
epithelial cells, placenta, 
T cells, thymus, 
microglia (activated) 
P2Y11 ATP 
NF546 
AR-C67085 
ATP-γ-S 
NF340  Spleen, intestine and granulocytes 
P2Y12 ADP 
2-MeSADP 
ADP-β-S 
AZD6140 
(Ticagrelor)   
AR-C69931MX 
(Cangrelor) 
PSB-0739 
MRS2395 
Platelets, glial cells 
P2Y13 ADP 2-MeSADP MRS2211  
Spleen, brain, lymph 
nodes, 
bone marrow, 
erythrocytes 
P2Y14 
UDP/ 
UDP-
glucose/ 
UDP-
galactose 
MRS2690 
MRS2802 
UDP may also 
act as antagonist 
Non-nucleotide 
antagonists have 
been reported 
Placenta, adipose tissue, 
stomach, intestine, 
discrete brain regions, 
mast cells 	  
Table 1: list of natural and some synthetic agonists, selective antagonists and main tissue 
distribution of P2Y purinergic receptors. 	  
 RECEPTOR EXPRESSION 
FUNCTIONAL 
RECEPTORS 
Neurons 
DRG P2X3 P2Y1,2,4,6,12,13,14 
P2X3 
P2Y1,2,12,13 
TG P2X3, P2X4 P2Y1,2,4,6 
P2X3 
P2Y1,2,4 
Dorsal horn spinal 
cord P2Y1,2,4,6 P2Y1,2,4,(6) 
Satellite glial 
cells 
DRG P2X7 P2Y1,12,14 
P2X7 
No functional studies 
on P2Y receptors 
TG P2X7 P2Y1,2,4,6,13,14 
P2X7 
P2Y1,2,4,6,13,14 
(P2Y12 under painful 
conditions) 
Astrocytes Dorsal horn spinal cord1 
P2X7 
P2Y1 (others?) 
P2X7 
P2Y1 (others?) 
Microglia Dorsal horn spinal cord 
P2X4, P2X7 
P2Y2,6,12,13,14 
P2X4, P2X7 
P2Y6,12,13,14 
Immune 
system cells  
P2X7 
P2Y1,2,4,6,12,14 
P2X7 
P2Y1,2,4,6,14 	  
Table 2: expression of purinergic P2X and P2Y receptor and demonstration of their 
functionality in the various cell types involved in pain transmission. The expression data 
could refer to either mRNA or protein evaluation. See text for details. 	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 No systematic evaluation of P2 receptor expression has been performed in spinal cord 
astrocytes. However, cortical brain astrocytes express a large range of P2X and P2Y receptors. 
See text for details. 
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MRS2211 
nerve injury 
chronic pain 
migraine? 
DRGs/TGs 
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Neuron 
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TRPV1 
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algogens 
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SPINAL CORD DORSAL HORN 
Microglial cells Astrocytes 
Neurons  
P2X7 
P2Y12 
P2Y6 
P2X4 
P2Y1 
other 
P2Y? 
DRGs  
P2X? 
P2Y1,2, 4 
P2X3 
P2X? 
P2Y13;14 
CCL21  
Microglial cells Astrocytes 
Neurons  
P2X7 
P2Y12 
P2Y6 
P2X4 
P2Y1 
other 
P2Y? 
DRGs  
P2X? 
P2Y1,2, 4 
P2X3 
P2X? 
P2Y13;14 
cytokines 
chemokines  
